Pfizer gets USFDA emergency use nod for Omicron BA.4/BA.5-adapted bivalent COVID booster in children under 5 years
New York: Pfizer Inc. and BioNTech SE have announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age (also referred to as under 5 years of age) at […] More